Prenetics Global Limited (NASDAQ: PRE) announced that its Board of Directors has approved a $40 million share‑repurchase program, allowing the company to buy back shares from the open market over an unspecified period. The program is intended to return capital to shareholders and support the share price as the company continues to focus on its consumer wellness platform.
The announcement comes after Prenetics has shifted its core business from diagnostics to the IM8 supplement brand, a move that has been accompanied by the divestiture of legacy diagnostics assets such as ACT Genomics, Europa Distribution, and Insighta. The company also paused its Bitcoin treasury purchases on December 4, 2025, and now holds only the Bitcoin acquired prior to that date.
Prenetics backs the buyback with a strong balance sheet, reporting $164 million in adjusted liquidity and a zero‑debt position. The share‑repurchase program is therefore a strategic use of excess cash that signals confidence in the company’s valuation and future growth prospects.
CEO Danny Yeung said, “We have spent the past year doing exactly what we said we would do — building IM8 into one of the fastest‑growing supplement brands in the world, strengthening our balance sheet, and eliminating complexity. Our $40 million share repurchase program is the natural next step: a direct expression of the Board’s view that the current share price does not yet reflect the underlying value and trajectory of this business.”
The announcement was well received by investors, reflecting confidence in Prenetics’s strategic pivot and the strong performance of the IM8 brand, which reached $120 million in annualized recurring revenue within 11 months of launch and is targeting $180 million to $200 million in revenue for 2026.
The share‑repurchase program underscores Prenetics’s commitment to returning value to shareholders while it continues to invest in the IM8 platform, aiming for adjusted EBITDA profitability by Q4 2027 and a continued focus on high‑margin consumer wellness products.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.